

## Research Article

# **Predicting Risk Factors of Acute Kidney Injury in the First 7 Days after Admission: Analysis of a Group of Critically Ill Patients**

# Kexin Wen, Yongqing Huang, Qi Guo, Tao Wu, Juanzhang Liu, Yuping Zheng, Shuxian Zhou<sup>(</sup>), and Dengfeng Geng<sup>(</sup>)

Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Correspondence should be addressed to Shuxian Zhou; zhoushux@mail.sysu.edu.cn and Dengfeng Geng; gengdf@mail.sysu.edu.cn

Received 21 September 2022; Revised 22 November 2022; Accepted 3 December 2022; Published 21 December 2022

Academic Editor: Arquimedes Gasparotto Junior

Copyright © 2022 Kexin Wen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Background.* Acute kidney injury (AKI) is a common complication in critically ill patients. Some predictive models have been reported, but the conclusions are controversial. The aim of this study was the formation of nomograms to predict risk factors for AKI in critically ill patients within the first 7 days after admission to the intensive care unit (ICU). *Methods.* Data were extracted from the Medical Information Mart for Intensive Care- (MIMIC-) III database. The random forest method was used to fill in the missing values, and least absolute shrinkage and selection operator (Lasso) regression analysis was performed to screen for possible risk factors. *Results.* A total of 561 patients were enrolled. Complication with AKI is significantly associated with a longer length of stay (LOS). For all patients, the predictors contained in the prediction nomogram included hypertension, coronary artery disease (CAD), cardiopulmonary bypass (CPB), coronary artery bypass grafting (CABG), Simplified Acute Physiology Score II (SAPS II), central venous pressure (CVP) measured for the first time after admission, and maximum and minimum mean artery pressure (MAP). The model showed good discrimination (C – index = 0.818, 95% CI: 0.779-0.857). In the subgroup of patients with well-controlled blood glucose levels, the significant predictors included hypertension, CABG, CPB, SAPS II, and maximum and minimum MAP. Good discrimination was also present before (C – index = 0.785, 95% CI: 0.736–0.834) and after adjustment (adjusted C – index = 0.770). *Conclusion.* Hypertension, CAD, CPB, CABG, SAPS II, CVP measured for the first time after admission, and maximum and minimum MAP were independent risk factors for AKI in critically ill patients.

## 1. Introduction

Acute kidney injury (AKI) is a serious clinical complication featuring both attributed morbidity and mortality in the short and long term [1–3]. Currently, there are a series of diagnostic criteria for AKI, including the risk, injury, failure, loss, and end-stage renal disease (RIFLE) [4], AKI Network (AKIN) [5], and Kidney Disease: Improving Global Outcomes (KDIGO) [6] classifications. Among different populations, the diverse diagnostic criteria correspond to the different incidences of AKI, which vary from 1% to 70% [7–9]. Given its significantly adverse effect on the prognosis of critically ill patients, early detection of potential AKI is vital [10]. As one of the classic and traditional predictors of renal insufficiency, serum creatinine has been labeled as limited now because of its unstable level in critically ill patients. Previous research reported that some prediction models incorporate age, the baseline estimated glomerular filtration rate (eGFR), N-terminal brain natriuretic peptide precursor (NT-proBNP), and some of the drugs affect kidney function, such as metformin and angiotensin converting enzyme inhibitor (ACEI). [11] Some results are still controversial. Also, a series of novel biomarkers, including urinary hemojuvelin (uHJV), kidney injury molecule-1 (uKIM-1), and neutrophil gelatinase-associated lipocalin (uNGAL), were also studied to better predict the occurrence of AKI [12, 13]. However, these markers are rarely used in the

TABLE 1: Differences between the demographic and clinical characteristics of the two groups.

Height (cm)167.94 ± 10.33170.26 ± 10.060.026BMI (m/kg²)28.56 ± 6.6329.55 ± 6.270.129APS III33.59 ± 15.2941.53 ± 18.440.0001First wardid12 (8)14 (3)0.837LoS1.64 (1.49)2.59 (3.41)0.0001Age6.2.41 ± 15.5066.6.46 ± 13.370.011SAPS1.673 ± 4.6119.46 ± 4.640.0011SAPS1.673 ± 4.6119.46 ± 4.640.0011SAPS1.673 ± 4.6119.46 ± 4.640.0011SAPS II28.67 ± 11.1936.17 ± 12.560.0002Einkauser vanvalraven2.31 ± 4.983.59 ± 6.110.0102Einkauser sids04.17 ± 8.596.82 ± 10.450.002Bihauser sids04.17 ± 8.596.82 ± 10.450.005Mingss15 (1)15 (0)0.163GCS <sub>moor</sub> 6 (1)6 (5)0.0101GCS <sub>moor</sub> 6 (1)6 (5)0.0001GCS <sub>moo</sub> 4 (1)3 (3)0.001GCS <sub>moon</sub> 7.50 ± 2.297.63 ± 2.020.540Glucose <sub>mon</sub> (nmol)9.67 ± 4.0810.55 ± 3.800.027Glucose <sub>mon</sub> (nmol)9.63 ± 1.036.58 ± 1.930.002Glucose <sub>mon</sub> (nmol)9.63 ± 1.636.58 ± 1.930.002Glucose <sub>mon</sub> (nmol)9.67 ± 4.0810.55 ± 3.800.027Glucose <sub>mon</sub> (nmol)9.67 ± 4.0810.55 ± 3.800.027Glucose <sub>mon</sub> (nmol)9.67 ± 4.0810.55 ± 3.200.500Glucose <sub>mon</sub> (nmol)9.67 ± 4.08 <th>Demographic characteristics</th> <th>No-AKI (<i>n</i> = 121)</th> <th>AKI (<i>n</i> = 440)</th> <th>P value</th>	Demographic characteristics	No-AKI ( <i>n</i> = 121)	AKI ( <i>n</i> = 440)	P value
BMI (m/kg <sup>2</sup> )         28.56 ± 6.63         29.55 ± 6.27         0.129           APS III         33.91 ± 13.29         41.63 ± 18.04         <0.001	Height (cm)	$167.94 \pm 10.33$	$170.26 \pm 10.06$	0.026
APS III         33.91 ± 13.29         41.53 ± 18.04         <0.001           First wardid         12 (8)         14 (3)         0.320           Lost wardid         14 (8)         14 (3)         0.687           LOS         1.64 (1.49)         2.39 (3.41)         <0.001	BMI (m/kg <sup>2</sup> )	$28.56 \pm 6.63$	$29.55 \pm 6.27$	0.129
First wardid     12 (8)     14 (3)     0.320       Last wardid     14 (8)     14 (3)     0.687       LOS     1.64 (1.49)     2.93 (5.41)     -0.001       Age     62.44 ± 15.90     66.46 ± 1.3.37     0.011       Weight     79.96 ± 22.74     85.41 ± 2.001     0.010       SAFS     16.73 ± 4.61     19.46 ± 4.64     -0.001       SOFA     3.08 ± 2.38     4.80 ± 2.73     -0.001       SAPS II     2.86 7 ± 11.19     36.17 ± 12.56     -0.001       Elix score     2.45 ± 5.544     4.86 ± 8.13     0.002       Elixhauser_sid29     2.74 ± 6.24     4.86 ± 8.13     0.002       Elixhauser_sid30     4.17 ± 8.59     6.68 ± 10.01     0.613       GCS. <sub>stat</sub> 5 (4.5)     1.85 (5)     0.001       GCS. <sub>stat</sub> 6 (1)     6 (5)     0.001       GCS. <sub>stat</sub> 14 (6)     10 (12)     0.001       Glucose <sub>man</sub> (mmol)     5.75 ± 1.83     5.39 ± 1.72     0.050       Glucose <sub>man</sub> (mmol)     9.67 ± 4.08     10.55 ± 3.80     0.027       Glucose <sub>man</sub> (mmol)     5.05 ± 1.02     0.010       Glucose <sub>man</sub> (mmol)     9.67 ± 4.08     10.51 ± 3.24     0.602       HA1 (%)     6.33 ± 1.63     6.304 ± 0.000     0.027       Glucose <sub>m</sub>	APS III	33.91 ± 13.29	$41.53 \pm 18.04$	< 0.001
Last wardid         14 (8)         14 (3)         0.687           LOS         1.64 (1.49)         2.39 (3.41)         <0.001	First wardid	12 (8)	14 (3)	0.320
LOS         1.44 (1.49)         2.39 (3.41)         <0.001	Last wardid	14 (8)	14 (3)	0.687
Age $62.44 \pm 15.90$ $66.46 \pm 13.37$ $0.011$ Weight79.96 ± 22.74 $85.41 \pm 20.01$ $0.010$ SAPS $16.73 \pm 4.61$ $19.46 \pm 4.64$ $<0.001$ SOFA $3.08 \pm 2.38$ $48.0 \pm 2.73$ $<0.001$ SAPS II $28.67 \pm 11.19$ $36.17 \pm 12.56$ $<0.001$ Elix acore $2.45 \pm 5.44$ $3.40 \pm 5.68$ $0.0098$ Elixhauser sunwalraven $2.31 \pm 4.98$ $3.59 \pm 6.11$ $0.010$ Elixhauser sid29 $2.74 \pm 6.24$ $48.6 \pm 8.13$ $0.002$ Elixhauser sid29 $2.74 \pm 6.24$ $48.6 \pm 8.13$ $0.001$ GCS <sub>moor</sub> $6(1)$ $15(0)$ $0.161$ GCS <sub>moor</sub> $6(1)$ $6(3)$ $0.001$ GCS <sub>moor</sub> $6(1)$ $3(3)$ $0.001$ GCS <sub>moon</sub> $6(1)$ $3(3)$ $0.001$ GCS <sub>moon</sub> $14.(6)$ $10.(12)$ $0.001$ GCS <sub>moon</sub> $14.60$ $10.022$ $0.001$ GLocse <sub>man</sub> (mmol) $7.59 \pm 2.29$ $7.63 \pm 2.02$ $0.502$ Glucse <sub>man</sub> (mmol) $7.59 \pm 2.29$ $7.63 \pm 2.02$ $0.602$ HBAIc (%) $633 \pm 1.63$ $6.58 \pm 1.93$ $0.021$ HBAIc (%) $633 \pm 1.63$ $6.58 \pm 1.93$ $0.021$ HBA <sub>Rux</sub> (bpm) $03.78 \pm 2.08$ $111.94 \pm 22.16$ $0.001$ CVP <sub>min</sub> (mHg) $5.55 \pm 11.78$ $50.20 \pm 12.84$ $0.001$ HB <sub>Rux</sub> (bpm) $0.35 \pm 4.04$ $0.52 \pm 1.321$ $0.264$ MAP <sub>max</sub> (mHg) $10.43 \pm 1.56$ $7.964 \pm 1.666$ $0.006$ MAP <sub>max</sub> (mHg) $10.43 \pm 1.$	LOS	1.64 (1.49)	2.39 (3.41)	< 0.001
Weight $79.96 \pm 22.74$ $85.41 \pm 20.01$ $0.010$ SAPS $16.73 \pm 4.61$ $19.46 \pm 4.64$ <0.001	Age	$62.41 \pm 15.90$	$66.46 \pm 13.37$	0.011
SAPS $16.73 \pm 4.61$ $19.46 \pm 4.64$ $<0.001$ SOFA $3.08 \pm 2.38$ $4.80 \pm 2.73$ $<0.001$ SAPS II $28.67 \pm 11.19$ $36.17 \pm 12.36$ $<0.001$ Elix score $2.45 \pm 5.44$ $3.69 \pm 6.11$ $0.019$ Elixhauser vanwalraven $2.31 \pm 4.98$ $3.59 \pm 6.11$ $0.002$ Elixhauser_sid29 $2.74 \pm 6.24$ $4.86 \pm 8.13$ $0.002$ Elixhauser_sid30 $4.17 \pm 8.59$ $6.82 \pm 10.45$ $0.005$ GCS_motor $6(1)$ $6(5)$ $0.010$ GCS_vetal $5(4.5)$ $1.85(5)$ $0.001$ GCS_vetal $4(1)$ $3(3)$ $0.001$ GCS_total $14(6)$ $10(12)$ $0.001$ Glucoseman (nmol) $5.75 \pm 1.83$ $5.39 \pm 1.72$ $0.550$ Glucoseman (nmol) $7.59 \pm 2.29$ $7.63 \pm 2.02$ $0.640$ Glucoseman (nmol) $7.59 \pm 2.29$ $7.63 \pm 2.02$ $0.640$ HA1c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ $0.193$ HA5c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ $0.193$ HA6m (hpm) $84.27 \pm 17.42$ $8.565 \pm 16.22$ $0.416$ HR <sub>man</sub> (bpm) $0.03.78 \pm 20.08$ $11.94 \pm 22.16$ $0.001$ CVP <sub>man</sub> (mHg) $0.03.78 \pm 20.08$ $11.94 \pm 22.16$ $0.001$ CVP <sub>man</sub> (mHg) $0.05.5 \pm 11.78$ $5.00 \pm 12.82$ $0.001$ MAP <sub>man</sub> (mHg) $0.55 \pm 1.178$ $0.20 \pm 12.83$ $0.013$ Temperature <sub>100</sub> (C) $3.59 \pm 1.63$ $3.06 \pm 23.67$ $0.006$ MAP <sub>man</sub> (mHg) $0.13.54 \pm 0.90$ $3.62 \pm 0.83$	Weight	$79.96 \pm 22.74$	$85.41\pm20.01$	0.010
SOFA $3.08 \pm 2.38$ $4.80 \pm 2.73$ <0.001SAPS II $28.67 \pm 11.19$ $36.17 \pm 12.56$ <0.001	SAPS	$16.73 \pm 4.61$	$19.46 \pm 4.64$	< 0.001
SAPS II $28.67 \pm 11.19$ $36.17 \pm 12.56$ $<0.001$ Elix core $2.45 \pm 5.44$ $3.40 \pm 5.68$ $0.098$ Elixhauser_axilazon $2.31 \pm 4.98$ $3.59 \pm 6.11$ $0.002$ Elixhauser_sid29 $2.74 \pm 6.24$ $4.86 \pm 8.13$ $0.002$ Elixhauser_sid20 $4.17 \pm 8.59$ $6.82 \pm 10.45$ $0.005$ Mingcs $15(1)$ $15(0)$ $0.163$ GCS_motor $6(1)$ $6(5)$ $0.001$ GCS_motor $6(1)$ $3(3)$ $0.001$ GCS_orgs $4(1)$ $3(3)$ $0.001$ Glucosemin (nmol) $5.75 \pm 1.83$ $5.91 \pm 1.72$ $0.620$ Glucosemin (nmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucosemin (nmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucosemin (nmol) $6.33 \pm 1.63$ $6.85 \pm 1.93$ $0.192$ Glucosemin (nmol) $6.33 \pm 1.63$ $6.85 \pm 1.93$ $0.192$ Glucosemin (nmol) $0.57 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucosemin (nmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucosemin (nmol) $0.37 \pm 1.742$ $8.565 \pm 16.22$ $0.602$ HBhar (%) $6.33 \pm 1.65$ $1.1.94 \pm 22.16$ $0.002$ HBhar (%) $10.378 \pm 2.08$ $11.1.94 \pm 2.216$ $0.002$ Remax (mml) $10.59 \pm 3.81$ $0.226$ $0.001$ MParin (mHg) $84.21 \pm 1.56$ $7.964 \pm 13.28$ $0.002$ MAP <sub>max</sub> (mmHg) $10.43 \pm 16.59$ $11.30 \pm 27.17$ $0.001$ Temperature <sub>max</sub> (C) $35.24 \pm 1.08$ $0.0$	SOFA	$3.08 \pm 2.38$	$4.80\pm2.73$	< 0.001
Elix score $2.45 \pm 5.44$ $3.40 \pm 5.68$ $0.098$ Elixhauser vanwalraven $2.31 \pm 4.98$ $3.59 \pm 6.11$ $0.019$ Elixhauser_sid29 $2.74 \pm 6.24$ $4.86 \pm 8.13$ $0.002$ Minges $15(1)$ $15(0)$ $0.163$ GCS_mote $6(1)$ $6.55$ $0.010$ GCS_weral $5(4.5)$ $1.85(5)$ $0.001$ GCS <sub>weral</sub> $14(6)$ $10(12)$ $0.001$ GCS <sub>weral</sub> $14(6)$ $10(12)$ $0.001$ GCS <sub>wera</sub> $14(6)$ $10.022$ $0.001$ GLucose <sub>mon</sub> (nmol) $5.75 \pm 1.83$ $5.39 \pm 1.72$ $0.050$ Glucose <sub>man</sub> (nmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.440$ Glucose <sub>man</sub> (nmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.440$ Glucose <sub>man</sub> (nmol) $6.33 \pm 1.63$ $6.85 \pm 1.93$ $0.193$ HbALc (%) $6.33 \pm 1.63$ $6.56 \pm 1.622$ $0.416$ HR <sub>min</sub> (bpm) $46.15 \pm 12.07$ $65.20 \pm 12.64$ $0.002$ HR <sub>min</sub> (bpm) $10.378 \pm 20.08$ $111.94 \pm 22.16$ $0.001$ CVP <sub>min</sub> (mH <sub>2</sub> O) $10.92 \pm 4.33$ $12.64 \pm 13.28$ $0.002$ MAP <sub>min</sub> (nmHg) $36.55 \pm 11.78$ $50.20 \pm 12.84$ $0.001$ MAP <sub>min</sub> (nmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $0.001$ MAP <sub>min</sub> (nmHg) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $0.001$ MAP <sub>min</sub> (nmHg) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $0.001$ MAP <sub>min</sub> (nmHg) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $0.001$ MPG <sub>min</sub> (v10-9/L) $10.47 \pm 2.12$	SAPS II	$28.67 \pm 11.19$	$36.17 \pm 12.56$	< 0.001
Elixhauser vanwalraven $2.31 \pm 4.98$ $3.59 \pm 6.11$ 0.019Elixhauser_sid29 $2.74 \pm 6.24$ $4.86 \pm 8.13$ 0.002Elixhauser_sid20 $4.17 \pm 8.59$ $6.82 \pm 10.45$ 0.005Mingcs $15(1)$ $15(0)$ 0.163GCS <sub>motor</sub> $6(1)$ $6(5)$ 0.010GCS <sub>verbal</sub> $5(4.5)$ $1.85(5)$ 0.001GCS <sub>ores</sub> $4(1)$ $3(3)$ 0.001GCS <sub>moto</sub> $14(6)$ $10(12)$ 0.001Glucose <sub>max</sub> (nmol) $5.75 \pm 1.83$ $5.39 \pm 1.72$ 0.050Glucose <sub>max</sub> (nmol) $7.50 \pm 2.29$ $7.64 \pm 2.02$ 0.740Glucose <sub>max</sub> (nmol) $6.33 \pm 1.63$ $6.58 \pm 1.93$ 0.027Glucose <sub>max</sub> (nmol) $6.33 \pm 1.63$ $6.58 \pm 1.93$ 0.019HbAl c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ 0.019HVArise (bpm) $84.27 \pm 17.42$ $85.65 \pm 16.22$ 0.416HR <sub>min</sub> (bpm) $64.53 \pm 12.07$ $65.20 \pm 12.64$ 0.602CVP <sub>min</sub> (cmH <sub>2</sub> O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ 0.001CVP <sub>min</sub> (cmH <sub>2</sub> O) $4.10 \pm 3.49$ $5.45 \pm 15.21$ 0.266MAP <sub>min</sub> (mmHg) $84.21 \pm 15.66$ $79.64 \pm 16.06$ 0.006MAP <sub>max</sub> (nmHg) $104.33 \pm 16.59$ $11.36 \pm 21.83$ 0.013Temperature <sub>min</sub> (C) $35.49 \pm 0.92$ $0.55 \pm 1.1.78$ $50.20 \pm 12.82$ $c.001$ MAP <sub>max</sub> (mHg) $10.43 \pm 12.56$ $79.64 \pm 16.06$ 0.006MAP <sub>max</sub> (nmHg) $10.47 \pm 2.12$ $9.52 \pm 0.77$ $c.001$ Hemoglobin <sub>min</sub> (g/L) $10$	Elix score	$2.45 \pm 5.44$	$3.40 \pm 5.68$	0.098
Elixhauser_sid29 $2.74 \pm 6.24$ $4.86 \pm 8.13$ $0.002$ Elixhauser_sid30 $4.17 \pm 8.59$ $6.82 \pm 10.45$ $0.005$ Minges $15(1)$ $15(0)$ $0.163$ GCS_motor $6(1)$ $6(5)$ $0.001$ GCS_vers $4(1)$ $3(3)$ $0.001$ GCS_vers $4(1)$ $3(3)$ $0.001$ GCS_vers $4(1)$ $3(3)$ $0.001$ GCS_vers $4(1)$ $3(3)$ $0.001$ Glucose_max (nmol) $5.75 \pm 1.83$ $5.91 \pm 1.72$ $0.050$ Glucose_max (nmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucose_max (nmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucose_max (nmol) $6.33 \pm 1.63$ $6.58 \pm 1.93$ $0.193$ HbA1c (%) $6.33 \pm 1.63$ $6.58 \pm 1.62$ $0.602$ HbMar (bpm) $84.27 \pm 17.42$ $8.65 \pm 16.22$ $0.616$ CVP_max (nmHg) $10.55 \pm 3.30$ $0.022$ $0.002$ CVP_max (nmHg) $10.55 \pm 1.321$ $0.266$ $0.006$ AMP_max (nmHg) $84.21 \pm 15.66$ $7.64 \pm 10.26$ $0.001$ CVP_min (nmHg) $56.55 \pm 11.78$ $30.22 \pm 0.83$ $0.013$ Temperature_max (C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature_max (C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin_max (g/L) $10.47 \pm 2.12$ $4.52 \pm 2.07$ $0.001$ Hemoglobin_max (g/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC <sub>max</sub> (ND9/L) $10.45 \pm 4.92$ $1.4.13 \pm 6.16$ $0.005$ </td <td>Elixhauser vanwalraven</td> <td><math>2.31 \pm 4.98</math></td> <td><math>3.59 \pm 6.11</math></td> <td>0.019</td>	Elixhauser vanwalraven	$2.31 \pm 4.98$	$3.59 \pm 6.11$	0.019
Elixhauser_sid30 $4.17 \pm 8.59$ $6.82 \pm 10.45$ $0.005$ Mingos15 (1)15 (0)0.163GCS motor6 (1)6 (5)0.010GCS evental5 (4.5)1.85 (5)0.001GCS evental14 (6)10 (12)0.001GCS evental14 (6)10 (12)0.001Glucose ement9.67 ± 4.081.95 ± 3.800.027Glucose ement9.67 ± 4.081.055 ± 3.800.027Glucose ement3.93 ± 3.955.16 ± 3.840.002Hahr6.33 ± 1.636.58 ± 1.930.193HAru10,55 ± 3.800.0270.601Glucose ement3.93 ± 3.955.16 ± 3.840.002HAru6.53 ± 1.0765.02 ± 0.610.602CVP min (bpm)64.33 ± 1.0765.02 ± 12.640.602CVP min (cmH_2O)10.50 ± 4.3312.64 ± 13.280.082CVP min (cmH_2O)4.10 ± 3.495.45 ± 13.210.266MAP min (mmHg)56.55 ± 1.7850.20 ± 12.640.001MAP min (mmHg)10.43 ± 16.5911.3.60 ± 7.77<0.001	Elixhauser_sid29	$2.74 \pm 6.24$	$4.86 \pm 8.13$	0.002
Minges15 (1)15 (0)0.163GCS notor6 (1)6 (5)0.010GCS_vetal5 (4.5)1.85 (5)0.001GCS_vetal4 (1)3 (3)0.001GCS_total14 (6)10 (12)0.001Glucose_max (mmol)5.75 ± 1.835.39 ± 1.720.050Glucose_max (mmol)9.67 ± 4.0810.55 ± 3.800.027Glucose_max (mmol)7.50 ± 2.297.63 ± 2.020.540Glucose_max (mmol)6.33 ± 1.636.58 ± 1.930.013HbA1c (%)6.33 ± 1.636.58 ± 1.930.193HR_nrt (bpm)84.27 ± 17.4285.65 ± 16.220.416HR_min (bpm)64.53 ± 12.0765.20 ± 12.640.602HR_mix (bpm)10.57 ± 4.3312.64 ± 13.280.002CVP_mix (mH2O)10.50 ± 4.3312.64 ± 13.280.002CVP_mix (mH2O)4.10 ± 3.495.45 ± 13.210.266MAP_mix (mmHg)104.33 ± 16.59113.60 ± 27.17<0.001	Elixhauser_sid30	$4.17 \pm 8.59$	$6.82 \pm 10.45$	0.005
$GC_{motor}$ $6(1)$ $6(5)$ $0.010$ $GC_{verbal}$ $5(45)$ $1.85(5)$ $0.001$ $GC_{verbal}$ $14(6)$ $10(12)$ $0.001$ $GC_{vorbal}$ $14(6)$ $10(12)$ $0.001$ $Glucose_{min}$ (nmol) $5.75\pm 1.83$ $5.39\pm 1.72$ $0.050$ $Glucose_{mean}$ (nmol) $9.67\pm 4.08$ $10.55\pm 3.80$ $0.027$ $Glucose_{mean}$ (nmol) $7.50\pm 2.29$ $7.63\pm 2.02$ $0.540$ $Glucose_{max}$ (nmol) $3.93\pm 3.95$ $5.16\pm 3.84$ $0.002$ $HbA1c$ (%) $6.33\pm 1.63$ $6.58\pm 1.93$ $0.192$ $HR_{max}$ (bpm) $84.27\pm 17.42$ $8.65\pm 16.22$ $0.416$ $HR_{min}$ (bpm) $64.53\pm 12.07$ $65.20\pm 12.64$ $0.602$ $HR_{min}$ (bpm) $103.78\pm 20.08$ $111.94\pm 22.16$ $<0.001$ $CVP_{first}$ (mH <sub>2</sub> O) $10.50\pm 4.33$ $12.64\pm 13.28$ $0.082$ $CVP_{min}$ (mHg) $84.21\pm 15.66$ $7.64\pm 16.06$ $0.006$ $MAP_{max}$ (nmHg) $104.33\pm 16.59$ $113.60\pm 7.17$ $<0.001$ $Temperature_{nint}$ (C) $35.92\pm 0.60$ $35.66\pm 0.96$ $0.006$ $Temperature_{mint}$ (C) $35.92\pm 0.60$ $35.66\pm 0.96$ $0.006$ $Temperature_{mint}$ (G) $10.94\pm 2.09$ $10.52\pm 2.19$ $0.064$ $Hemoglobin_{min}$ (g/L) $10.94\pm 2.09$ $10.52\pm 2.07$ $0.001$ $Temperature_{mint}$ (C) $35.92\pm 0.60$ $35.66\pm 0.96$ $0.006$ $Temperature_{mint}$ (C) $15.92\pm 1.63$ $0.052$ $0.006$ $Temperature_{mint}$ (GL) $10$	Mingcs	15 (1)	15 (0)	0.163
GCS verbal5 (4.5)1.85 (5)0.001GCS verbal4 (1)3 (3)0.001GCS votal14 (6)10 (12)0.001Glucose max (mmol)5.75 ± 1.835.39 ± 1.720.050Glucose max (mmol)9.67 ± 4.0810.55 ± 3.800.027Glucose max (mmol)7.50 ± 2.297.63 ± 2.020.540Glucose range (mmol)3.93 ± 3.955.16 ± 3.840.002HbAic (%)6.33 ± 1.636.58 ± 1.930.193HR mix (bpm)84.27 ± 17.4285.65 ± 16.220.416HR mix (bpm)0.05 ± 4.3312.64 ± 13.280.002CVP prix (cmH2O)10.50 ± 4.3312.64 ± 13.280.002CVP mix (cmH2O)0.05 ± 4.3312.64 ± 13.280.001MAP mix (mmHg)84.21 ± 15.6679.64 ± 16.060.006MAP mix (mmHg)104.33 ± 16.59113.60 ± 77.17<0.001	GCS <sub>motor</sub>	6 (1)	6 (5)	0.010
GCS eyes4 (1)3 (3)0.001GCs total14 (6)10 (12)0.001GCs total5.75 ± 1.835.39 ± 1.720.050Glucoseman (nmol)9.67 ± 4.0810.55 ± 3.800.027Glucoseman (nmol)7.50 ± 2.297.63 ± 2.020.540Glucoserange (nmol)3.93 ± 3.955.16 ± 3.840.002HbA1c (%)6.33 ± 1.636.58 ± 1.930.193HR first (bpm)84.27 ± 17.4285.65 ± 16.220.416HR min (bpm)64.53 ± 12.0765.20 ± 12.640.602HR max (bpm)103.78 ± 20.08111.94 ± 22.16<0.001	GCS <sub>verbal</sub>	5 (4.5)	1.85 (5)	0.001
GCS. total14 (6)10 (12)0.001Glucose min (nmol) $5.75 \pm 1.83$ $5.39 \pm 1.72$ 0.050Glucose ma (nmol) $9.67 \pm 4.08$ $10.55 \pm 3.80$ 0.027Glucose ma (nmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ 0.540Glucose range (nmol) $3.93 \pm 3.95$ $5.16 \pm 3.84$ 0.002HbA1c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ 0.133HR frat (bpm) $64.53 \pm 1.207$ $65.20 \pm 12.64$ 0.602HR min (bpm) $010.50 \pm 4.33$ $12.64 \pm 13.28$ 0.002CVP first (cmH2O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ 0.002CVP min (cmHg) $4.10 \pm 3.49$ $5.45 \pm 13.21$ 0.266MAP min (nmHg) $65.55 \pm 11.78$ $50.20 \pm 12.82$ <0.001	GCS <sub>eyes</sub>	4 (1)	3 (3)	0.001
Glucose_min (mmol) $5.75 \pm 1.83$ $5.39 \pm 1.72$ $0.050$ Glucose_max (mmol) $9.67 \pm 4.08$ $10.55 \pm 3.80$ $0.027$ Glucose_man (mmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucose_mage (mmol) $3.93 \pm 3.95$ $5.16 \pm 3.84$ $0.002$ HbA1c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ $0.193$ HR <sub>first</sub> (bpm) $84.27 \pm 17.42$ $85.65 \pm 16.22$ $0.416$ HR <sub>max</sub> (bpm) $013.78 \pm 20.08$ $111.94 \pm 22.16$ $0.602$ HR <sub>max</sub> (bpm) $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ CVP <sub>first</sub> (cmH <sub>2</sub> O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ CVP <sub>min</sub> (cmH <sub>2</sub> O) $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.266$ MAP <sub>first</sub> (mmHg) $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ MAP <sub>max</sub> (mmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature <sub>first</sub> (°C) $36.44 \pm 0.90$ $36.22 \pm 0.83$ $0.013$ Temperature <sub>min</sub> (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature <sub>min</sub> (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin <sub>first</sub> (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin <sub>min</sub> (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin <sub>min</sub> (g/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC <sub>min</sub> (x10.99/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC <sub>min</sub> (x10.99/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ Hemoglobin <sub>min</sub> (g/L) $10.45 \pm 4.04$ $11.52 \pm $	GCS <sub>total</sub>	14 (6)	10 (12)	0.001
Glucose_max (mmol) $9.67 \pm 4.08$ $10.55 \pm 3.80$ $0.027$ Glucose_man (mmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucose_range (mmol) $3.93 \pm 3.95$ $5.16 \pm 3.84$ $0.002$ HbA1c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ $0.193$ HR_fret (bpm) $84.27 \pm 17.42$ $85.65 \pm 16.22$ $0.416$ HR_min (bpm) $64.53 \pm 12.07$ $65.20 \pm 12.64$ $0.602$ HR_max (bpm) $103.78 \pm 20.08$ $111.94 \pm 22.16$ $0.001$ CVP_fret (cmH_2O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ CVP_min (cmH_2O) $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.606$ MAP_max (mmHg) $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ MAP_max (mmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature_frest (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature_min (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature_min (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin_min (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin_min (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin_mix (g/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.663$ WBC_max (x10.99L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ WBC_max (x10.99L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.007$ WBC_max (x10.99L) $12.58 \pm 91.50$ $190.16 \pm 90.12$ $0.016$	Glucose <sub>min</sub> (mmol)	$5.75 \pm 1.83$	$5.39 \pm 1.72$	0.050
Glucose mean (mmol) $7.50 \pm 2.29$ $7.63 \pm 2.02$ $0.540$ Glucose range (mmol) $3.93 \pm 3.95$ $5.16 \pm 3.84$ $0.002$ HbA1c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ $0.193$ HR first (bpm) $84.27 \pm 17.42$ $85.65 \pm 16.22$ $0.416$ HR min (bpm) $64.53 \pm 12.07$ $65.20 \pm 12.64$ $0.602$ HR max (bpm) $103.78 \pm 20.08$ $111.94 \pm 22.16$ $<0.001$ CVP first (cmH2O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ CVP min (cmH2O) $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.266$ MAP first (mmHg) $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ MAP min (mmHg) $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ MAP max (mmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature first (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature min (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin first (g/L) $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ Hemoglobin min (g/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.603$ WBC first (x10.9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.003$ WBC first (x10.9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ WBC first (x10.9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ WBC first (x10.9/L) $12.258 \pm 91.50$ $90.016 \pm 90.12$ $0.007$	Glucose <sub>max</sub> (mmol)	$9.67 \pm 4.08$	$10.55 \pm 3.80$	0.027
Glucose range (mmol) $3.93 \pm 3.95$ $5.16 \pm 3.84$ $0.002$ HbA1c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ $0.193$ HR first (bpm) $84.27 \pm 17.42$ $85.65 \pm 16.22$ $0.416$ HR min (bpm) $64.53 \pm 12.07$ $65.20 \pm 12.64$ $0.602$ HR max (bpm) $103.78 \pm 20.08$ $111.94 \pm 22.16$ $<0.001$ CVP first (cmH2O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ CVP min (cmH2O) $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.266$ MAP first (mmHg) $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ MAP max (mmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature max (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature max (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin min (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin min (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (x10^9/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC min (x10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ WBC first (x10^9/L) $12.40 \pm 4.92$ $10.91 \pm 5.45$ $0.016 \pm 90.12$ WBC min (x10^9/L) $12.95 \pm 91.50$ $190.16 \pm 90.12$ $0.016$	Glucose <sub>mean</sub> (mmol)	$7.50 \pm 2.29$	$7.63 \pm 2.02$	0.540
HbA1c (%) $6.33 \pm 1.63$ $6.58 \pm 1.93$ $0.193$ HR $84.27 \pm 17.42$ $85.65 \pm 16.22$ $0.416$ HR $6pm$ $64.53 \pm 12.07$ $65.20 \pm 12.64$ $0.602$ HR $nmx$ (bpm) $103.78 \pm 20.08$ $111.94 \pm 22.16$ $<0.001$ CVP $frst$ (cmH2O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ CVP $min$ (cmH2O) $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.266$ MAP $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ MAP $mmHg$ $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ MAP $max$ (mmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature $min$ (C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Hemoglobin $nin$ (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin $nin$ (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC $inst (x10^{\circ}9/L)$ $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC $inst (x10^{\circ}9/L)$ $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ UBC $inst (x10^{\circ}9/L)$ $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.007$	Glucose <sub>range</sub> (mmol)	$3.93 \pm 3.95$	$5.16 \pm 3.84$	0.002
HR hr hr min (bpm) $84.27 \pm 17.42$ $85.65 \pm 16.22$ $0.416$ HR min (bpm) $64.53 \pm 12.07$ $65.20 \pm 12.64$ $0.602$ HR max (bpm) $103.78 \pm 20.08$ $111.94 \pm 22.16$ $<0.001$ CVP frat (cmH2O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ CVP min (cmH2O) $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.266$ MAP first (mmHg) $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ MAP min (mmHg) $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ MAP max (mmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature first (°C) $36.44 \pm 0.90$ $36.22 \pm 0.83$ $0.013$ Temperature min (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature min (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin first (%IL) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin min (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (×10^9/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC min (×10^0/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC min (×10^0/PL) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ WBC min (×10^0/PL) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ WBC min (×10^0/PL) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.007$	HbA1c (%)	$6.33 \pm 1.63$	$6.58 \pm 1.93$	0.193
HR min (bpm) $64.53 \pm 12.07$ $65.20 \pm 12.64$ $0.602$ HR max (bpm) $103.78 \pm 20.08$ $111.94 \pm 22.16$ $<0.001$ CVP first (cmH2O) $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ CVP min (cmH2O) $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.266$ MAP first (mmHg) $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ MAP min (mmHg) $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ MAP max (mmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature first (°C) $36.44 \pm 0.90$ $36.22 \pm 0.83$ $0.013$ Temperature min (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin first (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin min (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC max (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT first (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT first (×10^9/L) $19.92 \pm 91.25$ $175.74 \pm 85.32$ $0.007$	HR <sub>first</sub> (bpm)	$84.27 \pm 17.42$	$85.65 \pm 16.22$	0.416
HR max (bpm)103.78 ± 20.08111.94 ± 22.16<0.001CVP first (cmH2O)10.50 ± 4.3312.64 ± 13.280.082CVP min (cmH2O)4.10 ± 3.495.45 ± 13.210.266MAP first (mmHg)84.21 ± 15.6679.64 ± 16.060.006MAP min (mmHg)56.55 ± 11.7850.20 ± 12.82<0.001	HR <sub>min</sub> (bpm)	$64.53 \pm 12.07$	$65.20 \pm 12.64$	0.602
$CVP_{first} (cmH_2O)$ $10.50 \pm 4.33$ $12.64 \pm 13.28$ $0.082$ $CVP_{min} (cmH_2O)$ $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.266$ $MAP_{first} (mmHg)$ $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ $MAP_{min} (mmHg)$ $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ $MAP_{max} (mmHg)$ $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ $Temperature_{first} (°C)$ $36.44 \pm 0.90$ $36.22 \pm 0.83$ $0.013$ $Temperature_{min} (°C)$ $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ $Temperature_{max} (°C)$ $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ $Hemoglobin_{first} (g/L)$ $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ $Hemoglobin_{max} (g/L)$ $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ $WBC_{first} (\times 10^{A}9/L)$ $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ $WBC_{max} (\times 10^{A}9/L)$ $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ $PLT_{first} (\times 10^{A}9/L)$ $212.58 \pm 91.50$ $190.16 \pm 90.12$ $0.016$	HR <sub>max</sub> (bpm)	$103.78\pm20.08$	$111.94 \pm 22.16$	< 0.001
$CVP_{min} (cmH_2O)$ $4.10 \pm 3.49$ $5.45 \pm 13.21$ $0.266$ $MAP_{first} (mmHg)$ $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ $MAP_{min} (mmHg)$ $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ $MAP_{max} (mmHg)$ $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature_{first} (°C) $36.44 \pm 0.90$ $36.22 \pm 0.83$ $0.013$ Temperature_min (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature_max (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin_first (g/L) $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ Hemoglobin_max (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC_first (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC_max (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT_first (×10^0/L) $212.58 \pm 91.50$ $190.16 \pm 90.12$ $0.016$	$CVP_{first}$ (cmH <sub>2</sub> O)	$10.50 \pm 4.33$	$12.64 \pm 13.28$	0.082
MAP first (mmHg) $84.21 \pm 15.66$ $79.64 \pm 16.06$ $0.006$ MAP min (mmHg) $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ MAP max (mmHg) $104.33 \pm 16.59$ $113.60 \pm 27.17$ $<0.001$ Temperature first (°C) $36.44 \pm 0.90$ $36.22 \pm 0.83$ $0.013$ Temperature min (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature max (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin first (g/L) $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ Hemoglobin min (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC max (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT first (×10^9/L) $122.58 \pm 91.50$ $190.16 \pm 90.12$ $0.016$	$CVP_{min}$ (cmH <sub>2</sub> O)	$4.10 \pm 3.49$	$5.45 \pm 13.21$	0.266
MAP_minfmmHg) $56.55 \pm 11.78$ $50.20 \pm 12.82$ $<0.001$ MAP_maxIMAP_max104.33 \pm 16.59113.60 $\pm 27.17$ $<0.001$ Temperature $36.44 \pm 0.90$ $36.22 \pm 0.83$ $0.013$ Temperature $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ Hemoglobin $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC $rst$ (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC $max$ (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT $rst$ (×10^9/L) $122.58 \pm 91.50$ $190.16 \pm 90.12$ $0.007$	MAP <sub>first</sub> (mmHg)	$84.21 \pm 15.66$	$79.64 \pm 16.06$	0.006
MAP max104.33 $\pm$ 16.59113.60 $\pm$ 27.17<0.001Temperature first36.44 $\pm$ 0.9036.22 $\pm$ 0.830.013Temperature min(°C)35.92 $\pm$ 0.6035.66 $\pm$ 0.960.006Temperature max(°C)37.82 $\pm$ 1.8339.66 $\pm$ 23.670.392Hemoglobin first(g/L)10.94 $\pm$ 2.0910.52 $\pm$ 2.190.064Hemoglobin min(g/L)10.47 $\pm$ 2.129.55 $\pm$ 2.07<0.001	MAP <sub>min</sub> (mmHg)	$56.55 \pm 11.78$	$50.20 \pm 12.82$	< 0.001
Temperature first (°C) $36.44 \pm 0.90$ $36.22 \pm 0.83$ $0.013$ Temperature min (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature max (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin first (g/L) $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ Hemoglobin min (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin max (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC max (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT first (×10^0/L) $212.58 \pm 91.50$ $190.16 \pm 90.12$ $0.007$	MAP <sub>max</sub> (mmHg)	$104.33 \pm 16.59$	$113.60 \pm 27.17$	< 0.001
Temperature min (°C) $35.92 \pm 0.60$ $35.66 \pm 0.96$ $0.006$ Temperature max (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin first (g/L) $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ Hemoglobin min (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin max (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC max (×10^9/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC max (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT first (×10^9/L) $212.58 \pm 91.50$ $190.16 \pm 90.12$ $0.016$	Temperature <sub>first</sub> (°C)	$36.44 \pm 0.90$	$36.22 \pm 0.83$	0.013
Temperature max (°C) $37.82 \pm 1.83$ $39.66 \pm 23.67$ $0.392$ Hemoglobin first (g/L) $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ Hemoglobin min (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin max (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC max (×10^9/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC max (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT first (×10^9/L) $212.58 \pm 91.50$ $190.16 \pm 90.12$ $0.016$ PLT max (×10^9/L) $199.92 \pm 91.25$ $175.74 \pm 85.32$ $0.007$	Temperature <sub>min</sub> (°C)	$35.92 \pm 0.60$	$35.66 \pm 0.96$	0.006
Hemoglobin first (g/L) $10.94 \pm 2.09$ $10.52 \pm 2.19$ $0.064$ Hemoglobin min (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ $<0.001$ Hemoglobin max (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC min (×10^9/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC max (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT first (×10^9/L) $212.58 \pm 91.50$ $190.16 \pm 90.12$ $0.016$	Temperature <sub>mar</sub> (°C)	$37.82 \pm 1.83$	$39.66 \pm 23.67$	0.392
Hemoglobin min (g/L) $10.47 \pm 2.12$ $9.55 \pm 2.07$ <0.001Hemoglobin max (g/L) $11.62 \pm 1.80$ $11.50 \pm 1.68$ $0.475$ WBC first (×10^9/L) $11.73 \pm 4.82$ $12.81 \pm 5.84$ $0.063$ WBC min (×10^9/L) $10.45 \pm 4.04$ $11.52 \pm 5.15$ $0.036$ WBC max (×10^9/L) $12.40 \pm 4.92$ $14.13 \pm 6.16$ $0.005$ PLT first (×10^9/L) $212.58 \pm 91.50$ $190.16 \pm 90.12$ $0.016$ PLT min (×10^9/L) $199.92 \pm 91.25$ $175.74 \pm 85.32$ $0.007$	Hemoglobin <sub>cart</sub> (g/L)	$10.94 \pm 2.09$	$10.52 \pm 2.19$	0.064
Hemoglobin max (g/L)11.62 $\pm$ 1.8011.50 $\pm$ 1.680.475WBC first (×10^9/L)11.73 $\pm$ 4.8212.81 $\pm$ 5.840.063WBC max (×10^9/L)10.45 $\pm$ 4.0411.52 $\pm$ 5.150.036WBC max (×10^9/L)12.40 $\pm$ 4.9214.13 $\pm$ 6.160.005PLT first (×10^9/L)212.58 $\pm$ 91.50190.16 $\pm$ 90.120.016PLT max (×10^9/L)199.92 $\pm$ 91.25175.74 $\pm$ 85.320.007	Hemoglobin (g/L)	$10.47 \pm 2.12$	$9.55 \pm 2.07$	< 0.001
Mining continue (c) D1000 $\pm$ 0.0000.000 $\pm$ 0.000WBC first (×10^9/L)11.73 $\pm$ 4.8212.81 $\pm$ 5.840.063WBC min (×10^9/L)10.45 $\pm$ 4.0411.52 $\pm$ 5.150.036WBC max (×10^9/L)12.40 $\pm$ 4.9214.13 $\pm$ 6.160.005PLT first (×10^9/L)212.58 $\pm$ 91.50190.16 $\pm$ 90.120.016PLT min (×10^9/L)199.92 $\pm$ 91.25175.74 $\pm$ 85.320.007	Hemoglobin $(g/L)$	$11.62 \pm 1.80$	$11.50 \pm 1.68$	0.475
WBC min (×10^9/L)10.45 $\pm$ 4.0411.52 $\pm$ 5.150.036WBC max (×10^9/L)12.40 $\pm$ 4.9214.13 $\pm$ 6.160.005PLT first (×10^9/L)212.58 $\pm$ 91.50190.16 $\pm$ 90.120.016PLT $\pm$ (×10^9/L)199.92 $\pm$ 91.25175.74 $\pm$ 85.320.007	$WBC_{\star} (\times 10^{9/1})$	$11.73 \pm 4.82$	$12.81 \pm 5.84$	0.063
WBC <sub>max</sub> (×10^9/L)12.40 $\pm$ 4.9214.13 $\pm$ 6.160.005PLT <sub>first</sub> (×10^9/L)212.58 $\pm$ 91.50190.16 $\pm$ 90.120.016PLT_+ (×10^9/L)199.92 $\pm$ 91.25175.74 $\pm$ 85.320.007	WBC $(\times 10^{9}/\text{I})$	$10.45 \pm 4.04$	11.52 + 5.15	0.005
PLT $(\times 10^{-9})L)$ $12.58 \pm 91.50$ $190.16 \pm 90.12$ $0.006$ PLT $(\times 10^{-9})L)$ $199.92 \pm 91.25$ $175.74 \pm 85.32$ $0.007$	$WBC (\times 10^{10})$	12 40 + 4 92	14 13 + 6 16	0.005
$PIT_{\text{first}} (x_{10}, y_{12}) = \frac{199.92 + 91.25}{175.74 + 85.32} = 0.007$	PIT. (x10/9/I)	$212.58 \pm 1.72$ $212.58 \pm 91.50$	190 16 + 90 12	0.005
	$PIT (\times 10^{10})$	199 92 + 91 25	175 74 + 85 32	0.010

#### Cardiovascular Therapeutics

TABLE 1: Continued.

Demographic characteristics	No-AKI ( <i>n</i> = 121)	AKI ( <i>n</i> = 440)	P value
PLT <sub>max</sub> (×10^9/L)	$221.23 \pm 91.67$	$210.56 \pm 86.29$	0.235
Angus sepsis, n (%)	12 (10)	83 (19)	0.029
Sedative, n (%)	51 (42)	307 (70)	< 0.001
Gender, n (%)	69 (57)	299 (68)	0.033
SIRS			0.005
0	3 (2)	3 (1)	
1	21 (17)	32 (7)	
2	31 (26)	107 (24)	
3	37 (31)	165 (38)	
4	29 (24)	133 (30)	
Ventilation, <i>n</i> (%)	54 (45)	327 (74)	< 0.001
Vasoactive drugs, <i>n</i> (%)	43 (36)	264 (60)	< 0.001
Congestive heart failure, $n$ (%)	3 (2)	25 (6)	0.231
Cardiac arrhythmias, $n$ (%)	5 (4)	29 (7)	0.430
Valvular disease, n (%)	1 (1)	10 (2)	0.471
Pulmonary circulation, <i>n</i> (%)	2 (2)	4 (1)	0.614
Peripheral vascular, <i>n</i> (%)	14 (12)	56 (13)	0.853
Hypertension, <i>n</i> (%)	6 (5)	57 (13)	0.021
Paralysis, n (%)	4 (3)	8 (2)	0.299
Other neurological, $n$ (%)	4 (3)	20 (5)	0.731
Chronic pulmonary, <i>n</i> (%)	14 (12)	71 (16)	0.272
Uncomplicated diabetes, $n$ (%)	25 (21)	128 (29)	0.084
Complicated diabetes, n (%)	3 (2)	21 (5)	0.395
All diabetes, n (%)	28 (23)	149 (34)	0.033
CHF, <i>n</i> (%)	28 (23)	141 (32)	0.075
Atrial fibrillation, $n$ (%)	25 (21)	154 (35)	0.004
Renal disease, n (%)	9 (7)	47 (11)	0.377
COPD, <i>n</i> (%)	7 (6)	43 (10)	0.237
CAD, <i>n</i> (%)	64 (53)	276 (63)	0.063
Stroke, <i>n</i> (%)	10 (8)	26 (6)	0.467
Malignancy, n (%)	10 (8)	39 (9)	0.980
Cardiopulmonary bypass, n (%)	36 (30)	259 (59)	< 0.001
CABG, <i>n</i> (%)	17 (14)	207 (47)	< 0.001
Left heart catheterization, $n$ (%)	54 (45)	159 (36)	0.110

Abbreviations: BMI: body mass index; APS III: autoimmune polyglandular syndrome type III; LOS: length of stay; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; SAPS II: Simplified Acute Physiology Score II; GCS: Glasgow coma scale; HbA1c: hemoglobin A1c; HR: heart rate; CVP: central venous pressure; MAP: mean arterial pressure; WBC: white blood cell; PLT: platelet; SIRS: systemic inflammatory response syndrome; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease; CABG: coronary artery bypass grafting.

clinic and lack sensitivity or specificity. Thus, it is vital to build models of efficiency that contain common clinical indicators to predict AKI. Then, nomograms are facilitated to visually exhibit the role of each risk factor. III database, which is composed of a large amount of clinical and test data collected from the ICU [15].

## 2. Methods

In our earlier study, we had explored the potential heterogeneity of AKI and evaluated the prognostic differences among AKI subphenotypes in critically ill patients with cardiovascular diseases [14]. In this study, we further built several nomograms of prediction models for different populations of AKI patients. The data were obtained from the Medical Information Mart for Intensive Care- (MIMIC-)

2.1. Data Source. The data in this study were extracted from the MIMIC-III (Medical Information Mart for Intensive Care) database established by Beth Israel Deaconess Medical Center in Boston, Massachusetts, USA [15]. This is a large, single-center database that is comprised of information relating to the patients admitted to critical care units and



FIGURE 1: Selection of the demographic and clinical features by using the LASSO binary logistic regression model. Notes: (a) Optimal parameter (lambda) selection in the LASSO model using fivefold cross-validation via minimum criteria. The partial likelihood deviance (binomial deviance) curve was plotted versus log(lambda). Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 SE of the minimum criteria (the 1-SE criteria). (b) LASSO coefficient profiles of the 51 features. A coefficient profile plot was produced against the log(lambda) sequence. A vertical line was drawn at the value selected using fivefold cross-validation, where optimal lambda resulted in five features with nonzero coefficients. Abbreviations: LASSO: least absolute shrinkage and selection operator; SE: standard error.



FIGURE 2: Developed ROC curve of the risk factors in the training set and test set. Abbreviations: ROC: receiver operator characteristic; AUC: area under the curve.

includes patient demographics, vital signs, medications, laboratory measurements, fluid balance, procedure and diagnostic codes, imaging reports, hospital length of stay, and death events. The use of the MIMIC-III database in this study was approved by the review committee of Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center.

2.2. Study Population. Patients older than 18 years old with a length of ICU stay longer than one day were included. For the patients who were recorded with multiple admissions, only the first ICU admission was extracted. Ultimately, 561 patients in the critical care units were enrolled for the following analysis.

2.3. Covariates and Outcomes. The baseline characteristics were extracted within the initial 24 hours after critical care unit admission. The covariates in this study included age, sex, body mass index (BMI), heart rate (HR), respiratory rate, oxygen saturation (SpO2), temperature, glucose, systolic blood pressure (SBP), diastolic blood pressure (DBP), 24-hour urine output, use of ventilation, stage of acute kidney injury at 48 hours and 7 days after admission, administration of vasopressors, sedatives, and furosemide.

The comorbidities included coronary artery disease (CAD), atrial fibrillation (AF), congestive heart failure (CHF), hypertension, stroke, sepsis, diabetes mellitus (DM), and chronic obstructive pulmonary disease (COPD), which were all recorded as International Classification of Diseases, Ninth Revision (ICD-9) codes. The procedures

TABLE 2: Prediction factors for AKI in critically ill patients.

Variable	β	OR	95% CI	P value
Hypertension	1.035	2.816	1.071-7.403	0.036
CAD	-0.72	0.487	0.271-0.874	0.016
Cardiopulmonary bypass	0.637	1.891	1.002-3.568	0.049
CABG	1.923	6.843	2.902-16.14	< 0.001
SAPS II	0.037	1.038	1.013-1.064	0.003
CVP <sub>first</sub>	0.1	1.105	1.042-1.171	0.001
MAP <sub>min</sub>	-0.037	0.963	0.941-0.986	0.002
MAP <sub>max</sub>	0.028	1.029	1.012-1.046	0.001

Note:  $\beta$  is the regression coefficient. Abbreviations: AKI: acute kidney injury; CAD: coronary artery disease; CABG: coronary artery bypass surgery; SAPS II: Simplified Acute Physiology Score II; CVP: central venous pressure; MAP: mean arterial pressure; OR: odds ratio; CI: confidence interval.

included cardiopulmonary bypass, coronary artery bypass grafting (CABG), and left heart catheterization.

The laboratory test measurements included the white blood cell (WBC) count and levels of hemoglobin, platelets, sodium, potassium, blood urea nitrogen (BUN), and creatinine. The severity at admission was measured by the Sequential Organ Failure Assessment (SOFA) score, Simplified Acute Physiology Score (SAPS), Simplified Acute Physiology Score II (SAPS II), Elixhauser comorbidity score, and length of ICU stay. The outcome of the current study was AKI.

2.4. Statistical Analyses. Continuous variables are presented as the SEM  $\pm$  SD or median (interquartile range), and



FIGURE 3: The developed medication nonadherence nomogram. Abbreviations: CAD: coronary artery disease; CABG: coronary artery bypass surgery; SAPS II: Simplified Acute Physiology Score II; CVP: central venous pressure; MAP: mean arterial pressure; AKI: acute kidney injury.

categorical variables are presented as numbers (percentages). The random forest method was used to fill in the missing values, and Student's t-test was used to compare significant differences in the data before and after filling. The chisquare test and the Kruskal-Wallis test were used for comparisons among the groups. After univariate binary logistic regression analysis, the least absolute shrinkage and selection operator (LASSO) method, which is suitable for the reduction in high-dimensional data [16, 17], was applied to select the optimal predictive features in the risk factors of critically ill patients. Eighty percent of the sample data were randomly selected as the training set and the remaining 20% as the fitting model of the test set. The odds ratio (OR) and 95% confidence interval (CI) values were determined by multivariate logistic regression to establish the final model. A two-tailed Pvalue < 0.05 was considered statistically significant. Statistical analyses were carried out by using SPSS (version 25.0, IBM, New York, USA) and the R tool (version 4.0.2, R Foundation for Statistical Computing, Vienna, Austria).

## 3. Results

#### 3.1. In All Statistics

*3.1.1. Patient Characteristics.* A total of 561 patients, consisting of 440 (78.43%) patients who were diagnosed with AKI in the first 7 days after admission to the ICU, were finally included in this study. There was no significant difference between the variables before and after filling. Their baseline information, including demographic, disease, and treatment features, in the two groups is shown in Table 1.

3.1.2. Feature Selection and Drawing of ROC Curve. After the univariate binary logistic regression analysis, 51 features with a Pvalue < 0.1 were put into the LASSO regression

model for further screening, as 80% of the data were randomly selected as the training set, and the remaining 20% were selected as the test set (Figures 1(a) and 1(b)). The ROC curves and AUC presented good predictive value of the model (Figure 2). The features included hypertension, CAD, cardiopulmonary bypass, CABG, SAPS II, CVP measured for the first time after admission, and maximum and minimum MAP during the ICU stay (Table 2).

*3.1.3. Development of the Prediction Model.* The results of multivariate logistic regression analysis are presented in Table 2. The model that incorporated the above independent predictors was developed and presented as the nomogram (Figure 3).

3.1.4. Apparent Performance of the Nonadherence Risk Nomogram in the Cohort. The C-index for the prediction nomogram was 0.818 (95% CI: 0.779-0.857) for the cohort and was confirmed to be 0.802 through bootstrapping validation, suggesting the model's good discrimination.

#### *3.2. In the HbA1c* < *6.5% Subgroup*

3.2.1. Patient Characteristics. The HbA1c < 6.5% subgroup contained 324 (73.63%) patients with AKI in the first 7 days after admission to the ICU. Their baseline information, including demographics, diseases, and treatment features, in the two groups is shown in Table 3.

3.2.2. Feature Selection and Drawing of the ROC Curve. Among the demographic, disease, and laboratory examination indexes, 34 features were put into the LASSO regression model for further screening, as 80% of the data were randomly selected as the training set and the remaining 20% as the test set (Figures 4(a) and 4(b)). The ROC curves and AUC presented good predictive value of the model

## Cardiovascular Therapeutics

TABLE 3: Differences between the demographic and clinical characteristics of the two groups in the HbA1c < 6.5% subgroup.

Demographic variables	No-AKI ( <i>n</i> = 93)	AKI ( <i>n</i> = 324)	P value
Height (cm)	$168.00 \pm 10.27$	$171.25 \pm 9.54$	0.005
BMI (m/kg <sup>2</sup> )	$28.38 \pm 7.15$	$29.45 \pm 6.28$	0.164
APS III	$35.18 \pm 13.66$	$42.18 \pm 18.69$	< 0.001
First wardid	12 (8)	14 (3)	0.393
Last wardid	14 (8)	14 (3)	0.968
Age	$63.11 \pm 15.35$	$65.62 \pm 13.45$	0.126
Weight	$79.52 \pm 24.46$	$86.02 \pm 20.09$	0.009
SAPS	$17.30 \pm 4.68$	$19.37 \pm 4.68$	< 0.001
SOFA	$3.32 \pm 2.50$	$4.88 \pm 2.86$	< 0.001
SAPS II	$29.77 \pm 11.78$	$36.31 \pm 13.05$	< 0.001
Elix score	$2.77 \pm 5.74$	$3.40 \pm 5.87$	0.359
Elixhauser vanwalraven	$2.60 \pm 5.11$	$3.56 \pm 6.15$	0.169
Elixhauser_sid29	$3.16 \pm 6.39$	$4.70\pm7.97$	0.055
Elixhauser_sid30	$4.78 \pm 8.94$	$6.74 \pm 10.41$	0.076
Mingcs	15 (1)	15 (0)	0.072
GCS <sub>motor</sub>	6 (2)	6 (5)	0.136
GCS <sub>verbal</sub>	5 (5)	1 (5)	0.020
GCS <sub>eyes</sub>	4 (1)	3 (3)	0.043
GCS <sub>total</sub>	14 (8)	10 (12)	0.057
Glucose <sub>min</sub> (mmol)	$5.64 \pm 1.92$	$5.43 \pm 1.75$	0.329
Glucose <sub>max</sub> (mmol)	$9.97 \pm 4.39$	$10.39 \pm 3.74$	0.356
Glucose <sub>mean</sub> (mmol)	$7.56 \pm 2.48$	$7.60 \pm 2.07$	0.887
Glucose <sub>range</sub> (mmol)	$4.33 \pm 4.21$	$4.96 \pm 3.76$	0.167
HbA1c (%)	$5.71 \pm 0.35$	$5.75 \pm 0.36$	0.369
HR <sub>first</sub> (bpm)	$84.34 \pm 17.17$	$86.05 \pm 16.86$	0.392
HR <sub>min</sub> (bpm)	$64.88 \pm 12.75$	$65.14 \pm 12.85$	0.866
HR <sub>max</sub> (bpm)	$104.53 \pm 19.69$	$112.82 \pm 22.76$	0.002
CVP <sub>first</sub> (cmH <sub>2</sub> O)	$10.71 \pm 4.31$	$12.83 \pm 15.19$	0.184
CVP <sub>min</sub> (cmH <sub>2</sub> O)	$4.05 \pm 3.52$	$5.77 \pm 15.25$	0.282
MAP <sub>first</sub> (mmHg)	$84.19 \pm 16.51$	$79.95 \pm 16.12$	0.027
MAP <sub>min</sub> (mmHg)	$56.19 \pm 11.43$	$49.66 \pm 13.00$	< 0.001
MAP <sub>max</sub> (mmHg)	$104.29 \pm 16.58$	$113.83 \pm 25.99$	0.001
Temperature <sub>first</sub> (°C)	$36.42\pm0.89$	$36.27\pm0.84$	0.125
Temperature <sub>min</sub> (°C)	$35.89\pm0.61$	$35.67 \pm 1.04$	0.057
Temperature <sub>max</sub> (°C)	$37.84 \pm 1.73$	$38.50 \pm 2.93$	0.041
Hemoglobin <sub>first</sub> (g/L)	$10.86\pm2.04$	$10.58 \pm 2.23$	0.289
Hemoglobin <sub>min</sub> (g/L)	$10.33\pm2.08$	$9.57 \pm 2.11$	0.002
Hemoglobin <sub>max</sub> (g/L)	$11.61 \pm 1.82$	$11.52 \pm 1.73$	0.686
WBC <sub>first</sub> (×10^9/L)	$11.87 \pm 5.13$	$12.88 \pm 5.77$	0.129
WBC <sub>min</sub> (×10^9/L)	$10.52 \pm 4.23$	$11.52 \pm 4.85$	0.073
WBC <sub>max</sub> (×10^9/L)	$12.57 \pm 5.24$	$14.11 \pm 5.94$	0.025
$PLT_{first}$ (×10^9/L)	$207.40 \pm 86.37$	$192.05 \pm 89.12$	0.141
PLT <sub>min</sub> (×10^9/L)	$193.76 \pm 86.57$	$178.97 \pm 87.06$	0.149
$PLT_{max}$ (×10^9/L)	$216.35 \pm 86.40$	$211.41 \pm 86.27$	0.627

TABLE 3: Continued.

Demographic variables	No-AKI ( <i>n</i> = 93)	AKI ( <i>n</i> = 324)	P value
Angus sepsis, n (%)	12 (13)	61 (19)	0.242
Sedative, n (%)	44 (47)	226 (70)	< 0.001
Gender, n (%)	55 (59)	231 (71)	0.036
SIRS, <i>n</i> (%)			0.016
Ventilation, <i>n</i> (%)	47 (51)	244 (75)	< 0.001
Vasoactive drugs, $n$ (%)	37 (40)	196 (60)	< 0.001
Congestive heart failure, n (%)	3 (3)	16 (5)	0.586
Cardiac arrhythmias, $n$ (%)	5 (5)	23 (7)	0.726
Valvular disease, n (%)	1 (1)	8 (2)	0.691
Pulmonary circulation, <i>n</i> (%)	2 (2)	3 (1)	0.310
Peripheral vascular, $n$ (%)	12 (13)	40 (12)	1.000
Hypertension, n (%)	5 (5)	43 (13)	0.055
Paralysis, n (%)	4 (4)	6 (2)	0.240
Other neurological, $n$ (%)	3 (3)	16 (5)	0.586
Chronic pulmonary, $n$ (%)	11 (12)	50 (15)	0.484
Diabetes uncomplicated, n (%)	20 (22)	95 (29)	0.175
Diabetes complicated, $n$ (%)	2 (2)	14 (4)	0.541
Diabetes all, n (%)	22 (24)	109 (34)	0.089
Furosemide, n (%)	11 (12)	37 (11)	1.000
CHF, <i>n</i> (%)	22 (24)	108 (33)	0.099
Atrial fibrillation, $n$ (%)	21 (23)	120 (37)	0.013
Renal disease, n (%)	7 (8)	35 (11)	0.466
Liver disease, $n$ (%)	1 (1)	8 (2)	0.691
COPD, <i>n</i> (%)	5 (5)	31 (10)	0.289
CAD, <i>n</i> (%)	50 (54)	199 (61)	0.227
Stroke, n (%)	8 (9)	24 (7)	0.872
Malignancy, n (%)	8 (9)	32 (10)	0.866
Cardiopulmonary bypass, n (%)	31 (33)	193 (60)	< 0.001
CABG, <i>n</i> (%)	17 (18)	151 (47)	< 0.001
Left heart catheterization, $n$ (%)	36 (39)	121 (37)	0.906

Abbreviations: BMI: body mass index; APS III: autoimmune polyglandular syndrome type III; LOS: length of stay; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; SAPS II: Simplified Acute Physiology Score II; GCS: Glasgow coma scale; HbA1c: Hemoglobin A1c; HR: heart rate; CVP: central venous pressure; MAP: mean arterial pressure; WBC: white blood cell; PLT: platelet; SIRS: systemic inflammatory response syndrome; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease; CABG: coronary artery bypass grafting.

(Figure 5). The features included hypertension, CABG, cardiopulmonary bypass, SAPS II, and maximum and minimum MAP during the ICU stay (Table 3).

*3.2.3. Development of the Prediction Model.* The results of the multivariate logistic regression analysis are presented in Table 4. The model that incorporated the above independent predictors was developed and presented as the nomogram (Figure 6).

3.2.4. Apparent Performance of the Nonadherence Risk Nomogram in the Cohort. The C-index for the prediction nomogram was 0.785 (95% CI: 0.736–0.834) for the cohort and was confirmed to be 0.770 through bootstrapping validation, suggesting the model's good discrimination.

## 4. Discussion

In this retrospective observational study, we reported an overall AKI incidence of 78.43% among a population of critically ill patients and an incidence of 73.63% in the subgroup of HbA1c < 6.5. Additionally, we built two nomograms for the critically ill patients enrolled and the subgroup of patients with HbA1c < 6.5. The predictive value of the models performed well in both the training set and test set. Even after adjustment, good discrimination still exists. The combination of clinical markers could better anticipate the development of AKI, helping doctors to be vigilant and eventually achieve further prevention of AKI.

AKI is a major complication with quite a high incidence in the ICU and is associated with increased treatment expenses and longer hospital stays [18]. Our study confirmed



FIGURE 4: Selection of the demographic and clinical features in the HbA1c < 6.5% subgroup by using the LASSO binary logistic regression model. Notes: (a) Optimal parameter (lambda) selection in the LASSO model using fivefold cross-validation via minimum criteria. The partial likelihood deviance (binomial deviance) curve was plotted versus log(lambda). Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 SE of the minimum criteria (the 1-SE criteria). (b) LASSO coefficient profiles of the 34 features. A coefficient profile plot was produced against the log(lambda) sequence. A vertical line was drawn at the value selected using fivefold cross-validation, where the optimal lambda resulted in five features with nonzero coefficients. Abbreviations: LASSO: least absolute shrinkage and selection operator; SE: standard error.

the high incidence of AKI in critically ill patients, which has been reported in other studies [19, 20]. The patients complicated with AKI had a higher 28-day mortality and increased LOS, suggesting the necessity to take strategies to reduce the morbidity of AKI. Although a series of studies have identified risk factors for AKI, there is still room for the development of risk prediction tools for AKI in critically ill patients. There have been a series of predictive models found in patients with contrast-induced AKI [21], underwent surgery [22], after liver transplantation [23], and with sepsis [24]. Recently, the standardized diagnostic and staging criteria for AKI have contributed to an improved understanding of the incidence and course of AKI in critically ill patients. However, there is still variation in its timely recognition,



FIGURE 5: Developed ROC curve of risk factors in the training set and test set in the HbA1c < 6.5% subgroup. Abbreviations: ROC: receiver operator characteristic; AUC: area under the curve.

TABLE 4: Prediction factors for AKI in the critically ill patients in the HbA1c < 6.5% subgroup.

Variable	β	OR	95% CI	P value
Hypertension	1.353	3.868	1.314-11.383	0.014
Cardiopulmonary bypass	0.794	2.213	1.126-4.347	0.021
CABG	0.897	2.452	1.159-5.189	0.019
SAPS II	0.028	1.029	1.003-1.054	0.026
MAP <sub>min</sub>	-0.044	0.957	0.933-0.983	0.001
MAP <sub>max</sub>	0.033	1.034	1.015-1.053	< 0.001

Note:  $\beta$  is the regression coefficient. Abbreviations: CABG: coronary artery bypass surgery; SAPS II: Simplified Acute Physiology Score II; MAP: mean arterial pressure; OR: odds ratio; CI: confidence interval.

management, and outcomes [1, 20]. There are novel biomarkers showing predictive value for AKI, including cystatin C, neutrophil gelatinase-associated lipocalin, interleukin-18, protein C, insulin-like growth factor-binding protein 7, tissue inhibitor of metalloproteinases-2, and kidney injury molecule-1. However, the sensitivity and specificity of these indicators are still high, and they are not routinely measured in clinical diagnosis and treatment work. The relatively high costs of the assays are another disadvantage.

To predict the occurrence of AKI more effectively and reduce its harm to patients, a combination of epidemiological, clinical, biological, and hereditary factors along with a series of biomarkers is required to be included in the ideal predictive models [25]. Medical Information Mart for Intensive Care (MIMIC), as one of public database of high quality, is widely used in evaluating clinical risks and building disease-prediction models owing to advantages of being highly valuable for data mining [26, 27]. Moreover, nomograms are widely used as prognostic devices in medicine. Applying multivariate logistic regression to build nomograms is accurate enough to help to better achieve userfriendly digital interfaces and more easily understood prognoses to make better clinical decisions [28].

In this study, data of 561 patients from MIMIC were used to build the models. It was found that hypertension, CAD, cardiopulmonary bypass, CABG, SAPS II, CVP measured for the first time after admission, and the maximum and minimum MAP during the ICU stay were significantly associated with an increased risk of AKI for critically ill patients in the first 7 days after admission. We founded two models of AKI with satisfactory AUCs of 0.762 and 0.672 and adjusted C-indexes of 0.802 and 0.770. After incorporated into nomograms, these clinical risk factors facilitated the prediction of AKI and possessed satisfying predictive value. Gujadhur et al. [29] reported a model from data of more than 2000 patients from intensive care unit (ICU), to predict development of AKI. The multiregression model included serum bicarbonate on admission (OR = 0.821; 95% CI: 0.796-0.846; P < 0.0001), APACHE III (OR = 1.011; 95% CI: 1.007-1.015; P < 0.0001), age (OR =1.016; 95% CI 1.008-1.024; P < 0.0001), and presence of sepsis at ICU admission (OR = 2.819; 95% CI: 2.122-23.744; P = 0.004), with an AUC of 0.8 (95% CI: 0.78-0.83). In our model, we also showed the association between a classic score which commonly used to assess physiological status of critically ill patients, SAPS II, and AKI. Another



FIGURE 6: The developed medication nonadherence nomogram in the HbA1c < 6.5% subgroup. Abbreviations: CABG: coronary artery bypass surgery; SAPS II: Simplified Acute Physiology Score II; MAP: mean arterial pressure; AKI: acute kidney injury.

model was developed, which contained heart failure, chronic kidney disease, emergency surgery, sepsis, and total bilirubin, to predict occurrence of critically ill patients, and the AUC (0.81), sensitivity (69.8%), and specificity (83.4%) were satisfactory [30]. Compared with Gujadhur A's model, this model contained more disease variables, which is also a feature of our model.

Published in 1993, the Simplified Acute Physiology Score (SAPS) II was developed and validated in a European and North American cohort and includes 17 variables collected during the first 24 hours of ICU stay [31]. The sum of the score represents the in-hospital mortality risk, and its predictive performance has been evaluated in multiple studies [32, 33]. Xu et al. also used the data from postcardiac surgery patients from the MIMIC-III database and reported better discriminative performances of both the 90-day mortality and 1-year mortality of the SAPS II scoring system than the SOFA scoring system [34]. SAPS II has been widely reported as an independent risk factor for AKI in different populations and different stages of AKI [35-37]. In our study, a similar positive result was concluded, suggesting the predictive value of SAPS II for the outcomes for critical patients.

AKI occurs in 2% to 30% of patients undergoing cardiac surgery [38]. It is largely assumed that the pathologic lesion of AKI after cardiac surgery is acute tubular necrosis [39]. The injured tubular epithelial cells slough, resulting in intratubular obstruction and hypertension. After the appearance of alterations in vasoreactivity, prerenal azotemia occurs, and cellular ATP depletion and oxidative injury eventually contribute to AKI. CPB is an intraoperative event associated with significant hemodynamic changes. Ischemicreperfusion injury is common following cardiopulmonary bypass (CPB) and causes AKI [40]. In a meta-analysis that enrolled 46 studies comprising 242,388 participants [41], a significant association between CPB under different diagnostic criteria for AKI was reported. Minute oxygen consumption (VO2) and perfusion pressure during CPB are the two major determinants affecting the local hemodynamics of the kidney. The steady, nonpulsatile nature of CPB negates the elastance, inertial, and reflective components of the arterial resistance during normal pulsatile flow, making the regulation of local perfusion pressure more important. However, the optimum parameters of CPB flow and pressure goals are not known. Moderately high levels were reported to be associated with a reduced incidence of cardiac and neurologic complications, but the renal function was not assessed simultaneously [42].

It is worth noting that the relationship between CAD and AKI was anomalous. Yayan [43] compared occurrence of AKI after PCI of patients with and without CAD. Results showed that the occurrence of AKI was not significantly related to the presence of coronary heart disease (P = 0.95, chi-square test). In our study, the baseline presence of CAD and AKI is not associated (P = 0.050, chi-square test), neither. And after Lasso regression and multiple regression analysis, CAD was positively related to AKI. Combined with the results of this study, we speculated the difference of definitions and diagnostic criteria of AKI led to this abnormal result. However, there being no research elaborated the nonsignificant even positive relationship between CAD and AKI, future studies featured as more patients and prospective data collection with diagnostic criteria of AKI more applicable to Chinese are needed to solve this problem.

We believe our work provides clinicians with a new tool to identify patients with a high risk of AKI and the requirements of preventive strategies. The risk scores based on the parameters that are available to clinicians are higher, as they are faster and easier to obtain. Moreover, cheaper and more valid biomarkers, whose level is less affected by other factors, still need to be explored to evaluate changes in renal function. More sophisticated and effective models to predict AKI are needed for the prevention and intervention of adverse outcomes. There were several limitations that should be mentioned in our current study. First, the cohort could not represent all critically ill patients as those who without access to treatment were not included. Second, all comorbidities were recorded by ICD-9 codes, which might satisfy the latest diagnostic criteria for some diseases. Third, in all critically ill patients included in our study, CAD is a protective factor. As being analyzed, it is because of the inevitable deficiencies of the retrospective design, such as failure to assess patients' status in a timely manner and limitations on the number of cases. Therefore, future studies featured as more patients and prospective data collection are needed to help enhance the credibility of our results.

## 5. Conclusion

This study applied a novel nomogram with relatively good accuracy to assess the risk of AKI in critically ill patients. Eventually, hypertension, CAD, cardiopulmonary bypass, CABG, SAPS II, CVP measured for the first time after admission, and maximum and minimum MAP during the ICU stay were independent risk factors for AKI for critically ill patients within the first 7 days of admission. Further study is needed to reveal the potential mechanisms.

## **Data Availability**

The data used to support the findings of this study are included within the article.

## **Ethical Approval**

The use of the MIMIC-III database was approved by the review committee of Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center. Ethical approval was obtained from the Sun Yat-sen Memorial Hospital, Sun Yat-sen University ethics committee. All subjects/legal guardians gave written informed consent and assent as appropriate. The protocol was performed in accordance with the Declaration of Helsinki.

## **Conflicts of Interest**

The authors declare that there is no conflict of interest regarding the publication of this article.

## **Authors' Contributions**

Kexin Wen and Yongqing Huang designed the study and wrote the main manuscript text. Qi Guo obtained the data from MIMIC-III. Tao Wu prepared Figures 1–6. Juanzhang Liu and Yuping Zheng prepared Tables 1–4. Shuxian Zhou and Dengfeng Geng proposed amendments to the manuscript. All authors made significant contributions to this study and reviewed the manuscript. Kexin Wen and Yongqing Huang contributed equally to this work.

### Acknowledgments

We would like to thank the participants, developers, and investigators associated with the MIMIC-III database. This research is funded by the Sun Yat-Sen Clinical Research Cultivating Program (SYS-C-202101), the Guangzhou Science and Technology Plan Project (202102010312), the Hypertension Research and Innovation Fund of Chinese Cardiovascular Association (2021-CCA-HTN-40), the Chinese Cardiovascular Association-Access Fund (2021-CCA-ACCESS-166), and the Natural Science Foundation of Guangdong Province (2018A030313531).

## References

- E. A. Hoste, S. M. Bagshaw, R. Bellomo et al., "Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study," *Intensive Care Medicine*, vol. 41, no. 8, pp. 1411–1423, 2015.
- [2] S. Nisula, The FINNAKI Study Group, K.-M. Kaukonen et al., "Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study," *Intensive Care Medicine*, vol. 39, no. 3, pp. 420–428, 2013.
- [3] H. Gammelager, C. F. Christiansen, M. B. Johansen, E. Tønnesen, B. Jespersen, and H. T. Sørensen, "One-year mortality among Danish intensive care patients with acute kidney injury: a cohort study," *Critical Care*, vol. 16, no. 4, p. R124, 2012.
- [4] R. Bellomo, C. Ronco, J. A. Kellum, R. L. Mehta, P. Palevsky, and Acute Dialysis Quality Initiative workgroup, "Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group," *Critical Care*, vol. 8, no. 4, pp. R204–R212, 2004.
- [5] R. L. Mehta, J. A. Kellum, S. V. Shah et al., "Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury," *Critical Care*, vol. 11, no. 2, p. R31, 2007.
- [6] J. A. Kellum, N. Lameire, and for the KDIGO AKI Guideline Work Group, "Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1)," *Critical Care*, vol. 17, no. 1, p. 204, 2013.
- [7] J. Koeze, F. Keus, W. Dieperink, I. C. van der Horst, J. G. Zijlstra, and M. van Meurs, "Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria," *BMC Nephrology.*, vol. 18, no. 1, p. 70, 2017.
- [8] J. Case, S. Khan, R. Khalid, and A. Khan, "Epidemiology of acute kidney injury in the intensive care unit," *Critical Care Research and Practice*, vol. 2013, Article ID 479730, 9 pages, 2013.
- [9] G. M. Chertow, E. Burdick, M. Honour, J. V. Bonventre, and D. W. Bates, "Acute kidney injury, mortality, length of stay, and costs in hospitalized patients," *Journal of the American Society of Nephrology*, vol. 16, no. 11, pp. 3365–3370, 2005.

- [10] A. Zarbock, J. A. Kellum, C. Schmidt et al., "Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial," *Journal of the American Medical Association*, vol. 315, no. 20, pp. 2190–2199, 2016.
- [11] P. Dennen, I. S. Douglas, and R. Anderson, "Acute kidney injury in the intensive care unit: an update and primer for the intensivist," *Critical Care Medicine*, vol. 38, no. 1, pp. 261–275, 2010.
- [12] J. J. Wang, N. H. Chi, T. M. Huang et al., "Urinary biomarkers predict advanced acute kidney injury after cardiovascular surgery," *Critical Care*, vol. 22, no. 1, p. 108, 2018.
- [13] M. Wang, Q. Zhang, X. Zhao, G. Dong, and C. Li, "Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the emergency department: an observational study," *Critical Care*, vol. 18, no. 6, p. 634, 2014.
- [14] Y. Huang, Z. Xiao, Y. Xie et al., "Association of latent class analysis-derived subphenotypes of acute kidney injury with mortality in critically ill patients with cardiovascular disease: a retrospective cohort study," *BMC Cardiovascular Disorders*, vol. 22, no. 1, p. 154, 2022.
- [15] A. E. Johnson, T. J. Pollard, L. Shen et al., "MIMIC-III, a freely accessible critical care database," *Scientific Data*, vol. 3, no. 1, article 160035, 2016.
- [16] J. Friedman, T. Hastie, and R. Tibshirani, "Regularization paths for generalized linear models via coordinate descent," *Journal of Statistical Software*, vol. 33, no. 1, pp. 1–22, 2010.
- [17] W. Sauerbrei, P. Royston, and H. Binder, "Selection of important variables and determination of functional form for continuous predictors in multivariable model building," *Statistics in Medicine*, vol. 26, no. 30, pp. 5512–5528, 2007.
- [18] C. Hobson, T. Ozrazgat-Baslanti, A. Kuxhausen et al., "Cost and mortality associated with postoperative acute kidney injury," *Annals of Surgery.*, vol. 261, no. 6, pp. 1207–1214, 2015.
- [19] J. A. Kellum, F. E. Sileanu, R. Murugan, N. Lucko, A. D. Shaw, and G. Clermont, "Classifying AKI by urine output versus serum creatinine level," *Journal of the American Society of Nephrology*, vol. 26, no. 9, pp. 2231–2238, 2015.
- [20] J. Bouchard, A. Acharya, J. Cerda et al., "A prospective international multicenter study of AKI in the intensive care unit," *Clinical Journal of the American Society of Nephrology*, vol. 10, no. 8, pp. 1324–1331, 2015.
- [21] R. Mehran, E. D. Aymong, E. Nikolsky et al., "A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation," *Journal of the American College of Cardiology*, vol. 44, no. 7, pp. 1393–1399, 2004.
- [22] C. V. Thakar, S. Arrigain, S. Worley, J. P. Yared, and E. P. Paganini, "A clinical score to predict acute renal failure after cardiac surgery," *Journal of the American Society of Nephrol*ogy, vol. 16, no. 1, pp. 162–168, 2005.
- [23] I. Umbro, F. Tinti, I. Scalera et al., "Acute kidney injury and post-reperfusion syndrome in liver transplantation," *World Journal of Gastroenterology*, vol. 22, no. 42, pp. 9314–9323, 2016.
- [24] F. Deng, M. Peng, J. Li, Y. Chen, B. Zhang, and S. Zhao, "Nomogram to predict the risk of septic acute kidney injury

in the first 24 h of admission: an analysis of intensive care unit data," *Renal Failure*, vol. 42, no. 1, pp. 428–436, 2020.

- [25] C. Moriates and A. Maisel, "The utility of biomarkers in sorting out the complex patient," *The American Journal of Medicine*, vol. 123, no. 5, pp. 393–399, 2010.
- [26] J. Yang, Y. Li, Q. Liu et al., "Brief introduction of medical database and data mining technology in big data era," *Journal of Evidence-Based Medicine*, vol. 13, no. 1, pp. 57–69, 2020.
- [27] W. T. Wu, Y. J. Li, A. Z. Feng et al., "Data mining in clinical big data: the frequently used databases, steps, and methodological models," *Military Medical Research*, vol. 8, no. 1, p. 44, 2021.
- [28] H. Wang, L. Zhang, Z. Liu et al., "Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram," *Patient Preference and Adherence.*, vol. 12, pp. 1757–1765, 2018.
- [29] A. Gujadhur, R. Tiruvoipati, E. Cole, S. Malouf, E. S. Ansari, and K. Wong, "Serum bicarbonate may independently predict acute kidney injury in critically ill patients: an observational study," *World Journal of Critical Care Medicine.*, vol. 4, no. 1, pp. 71–76, 2015.
- [30] Y. Chen, F. Feng, M. Li, X. Chang, B. Wei, and C. Dong, "Development of a risk stratification-based model for prediction of acute kidney injury in critically ill patients," *Medicine*, vol. 98, no. 33, article e16867, 2019.
- [31] J. R. Le Gall, S. Lemeshow, and F. Saulnier, "A new simplified acute physiology score (SAPS II) based on a European/north American multicenter study," *Journal of the American Medical Association*, vol. 270, no. 24, pp. 2957–2963, 1993.
- [32] D. A. Harrison, A. R. Brady, G. J. Parry, J. R. Carpenter, and K. Rowan, "Recalibration of risk prediction models in a large multicenter cohort of admissions to adult, general critical care units in the United Kingdom," *Critical Care Medicine*, vol. 34, no. 5, pp. 1378–1388, 2006.
- [33] O. A. Haaland, F. Lindemark, H. Flaatten, R. Kvåle, and K. A. Johansson, "A calibration study of SAPS II with Norwegian intensive care registry data," *Acta Anaesthesiologica Scandinavica*, vol. 58, no. 6, pp. 701–708, 2014.
- [34] F. Xu, W. Li, C. Zhang, and R. Cao, "Performance of sequential organ failure assessment and simplified acute physiology score II for post-cardiac surgery patients in intensive care unit," *Frontiers in Cardiovascular Medicine*, vol. 8, article 774935, 2021.
- [35] R. Lombardi, N. Nin, O. Peñuelas et al., "Acute kidney injury in mechanically ventilated patients," *Shock*, vol. 48, no. 4, pp. 411–417, 2017.
- [36] H. R. Chua, W. K. Wong, V. H. Ong et al., "Extended mortality and chronic kidney disease after septic acute kidney injury," *Journal of Intensive Care Medicine*, vol. 35, no. 6, pp. 527– 535, 2020.
- [37] K. Chaudhary, A. Vaid, Á. Duffy et al., "Utilization of deep learning for subphenotype identification in sepsis-associated acute kidney injury," *Clinical Journal of the American Society* of Nephrology: CJASN, vol. 15, no. 11, pp. 1557–1565, 2020.
- [38] M. H. Rosner and M. D. Okusa, "Acute kidney injury associated with cardiac surgery," *Clinical Journal of the American Society of Nephrology: CJASN.*, vol. 1, no. 1, pp. 19–32, 2006.
- [39] S. M. Moran and B. D. Myers, "Pathophysiology of protracted acute renal failure in man," *The Journal of Clinical Investigation*, vol. 76, no. 4, pp. 1440–1448, 1985.

- [40] S. Uchino, J. A. Kellum, R. Bellomo et al., "Acute renal failure in critically ill patients: a multinational, multicenter study," *Journal of the American Medical Association*, vol. 294, no. 7, pp. 813–818, 2005.
- [41] J. W. Pickering, M. T. James, and S. C. Palmer, "Acute kidney injury and prognosis after cardiopulmonary bypass: a metaanalysis of cohort studies," *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation.*, vol. 65, no. 2, pp. 283–293, 2015.
- [42] J. P. Gold, M. E. Charlson, P. Williams-Russo et al., "Improvement of outcomes after coronary artery bypass: a randomized trial comparing intraoperative high versus low mean arterial pressure," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 110, no. 5, pp. 1302–1314, 1995.
- [43] J. Yayan, "Coronary heart disease is not significantly linked to acute kidney injury identified using acute kidney injury group criteria," *International Journal of General Medicine*, vol. 5, pp. 831–838, 2012.